<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868218</url>
  </required_header>
  <id_info>
    <org_study_id>PANFLUVAC-2008, Version 2</org_study_id>
    <secondary_id>EU PANFLUVAC 44115</secondary_id>
    <nct_id>NCT00868218</nct_id>
  </id_info>
  <brief_title>Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults</brief_title>
  <acronym>PANFLUVAC</acronym>
  <official_title>Preparing for an Influenza Pandemic: A Phase I Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rebecca Cox</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and tolerability of the pandemic A/H5N1 virosomal vaccine formulated with or
      without the 3rd generation ISCOM™ adjuvant for parenteral administration will be investigated
      locally and systemically and by using haematological, biochemical and immunological screening
      tests. The immunogenicity of the H5N1 vaccine will be assessed through the induction of local
      and systemic antibody and cellular immune responses. In a pandemic situation, an important
      aspect is the rapidity of the immune response to the H5N1 vaccine so the detailed kinetics of
      the immune response will be investigated. The capacity of the vaccine to elicit long lasting
      immunity and cross reactive immunity to H5 viruses will also be evaluated. Furthermore, the
      quality of the immune response induced by the vaccine will be studied. The vaccine will be
      administered as twice the normal human dose (30μg HA) with and without adjuvant, and in a
      dose sparing manor of half (7.5μg HA) and one tenth (1.5μg HA) of the normal human dose with
      adjuvant. Sixty subjects will receive two doses of virosomal H5N1 influenza vaccine
      (separated by 21 ± 4 days) by intramuscular injection into the deltoid muscle. Escalating
      doses will be separated by a period of one week. Four groups each containing 15 subjects will
      receive two doses of the pandemic virosomal A/H5N1 influenza vaccine containing:

      Group 1 30µg HA IM, Group 2 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 3
      7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 4 30µg HA adjuvanted with 50µg
      3rd generation ISCOM™ IM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicted Adverse Events</measure>
    <time_frame>three months</time_frame>
    <description>The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine</measure>
    <time_frame>one year</time_frame>
    <description>Number of participants with haemagglutination inhibition tigers &gt;= 32 at the long term time point (1 year post vaccination).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Influenza</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30µg HA vaccine Intramuscularly administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers (as concluded from the medical history, physical examination, and
             clinical judgment) aged 19 to 50 years old

          -  Females using a reliable method of contraception (from 4 weeks prior to the first
             vaccination until 4 weeks after the second vaccination) and a negative urine pregnancy
             test will be required before administration of each dose of vaccine

          -  Signed informed consent

          -  Subjects able to understand and comply with the study protocol and complete the
             Adverse Event Form

          -  Subjects able to attend the scheduled visits

          -  Subjects with normal pre-screening values. If a subjects prescreening samples lie
             outside the reference values he/she will only be included in the study based upon the
             medical evaluation of the clinical investigator

        Exclusion Criteria:

          -  Persons with a history of anaphylaxis or serious reactions to any vaccine

          -  Persons with known hypersensitivity to any of the vaccine components

          -  Persons who have had a temperature &gt;38oC during the previous 72 hours

          -  Persons who have had an acute respiratory infection during the last 7 days

          -  Women who are pregnant or breast-feeding

          -  Persons with chronic illness at any stage that could interfere with trial conduct or
             compliance

          -  Persons who have received blood products or immunoglobulins parenterally during the
             previous 3 months

          -  Persons who have been vaccinated with any vaccine during the 4 weeks preceding the
             first trial vaccination

          -  Persons with known or suspected immunosuppressive disease or who use systemic
             immunosuppressive drugs

          -  Persons taking immunostimulant therapy

          -  Persons involved in another clinical trial during the last month.

          -  Suspected non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haakon Sjursen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Haukeland Univeristy Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland Univeristy Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis. 2012 Jul 15;206(2):158-66. doi: 10.1093/infdis/jis330. Epub 2012 May 2.</citation>
    <PMID>22551811</PMID>
  </results_reference>
  <results_reference>
    <citation>Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine. 2011 Oct 19;29(45):8049-59. doi: 10.1016/j.vaccine.2011.08.042. Epub 2011 Aug 22.</citation>
    <PMID>21864624</PMID>
  </results_reference>
  <results_reference>
    <citation>Pedersen GK, Sjursen H, Nøstbakken JK, Jul-Larsen Å, Hoschler K, Cox RJ. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother. 2014;10(8):2408-16. doi: 10.4161/hv.29583.</citation>
    <PMID>25424948</PMID>
  </results_reference>
  <results_reference>
    <citation>Pedersen GK, Höschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 2014 Jul 31;32(35):4550-7. doi: 10.1016/j.vaccine.2014.06.009. Epub 2014 Jun 18.</citation>
    <PMID>24950357</PMID>
  </results_reference>
  <results_reference>
    <citation>Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, Roseby S, Bredholt G, Assmus J, Breakwell L, Campitelli L, Sjursen H. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets. PLoS One. 2015 Jul 6;10(7):e0131652. doi: 10.1371/journal.pone.0131652. eCollection 2015.</citation>
    <PMID>26147369</PMID>
  </results_reference>
  <results_reference>
    <citation>Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.</citation>
    <PMID>25210189</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <results_first_submitted>June 6, 2015</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2016</results_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Bergen</investigator_affiliation>
    <investigator_full_name>Rebecca Cox</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Influenza A</keyword>
  <keyword>pandemic</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>Virus</keyword>
  <keyword>H5N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Haukeland University hospital recrutiment in 2009</recruitment_details>
      <pre_assignment_details>Haelthy person were randomly assigned to one of 4 vaccine groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>30µg HA Vaccine</title>
          <description>30µg HA vaccine Intramuscularly administered Influenza vaccine: Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="P2">
          <title>1.5µg HA Adjuvanted</title>
          <description>1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="P3">
          <title>7.5µg HA Adjuvanted</title>
          <description>7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="P4">
          <title>30µg HA Adjuvanted</title>
          <description>30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy adults willing to join phase I trial</population>
      <group_list>
        <group group_id="B1">
          <title>30µg HA Vaccine</title>
          <description>30µg HA vaccine Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="B2">
          <title>1.5µg HA Adjuvanted</title>
          <description>1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="B3">
          <title>7.5µg HA Adjuvanted</title>
          <description>7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="B4">
          <title>30µg HA Adjuvanted</title>
          <description>30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="21" upper_limit="41"/>
                    <measurement group_id="B2" value="29" lower_limit="21" upper_limit="44"/>
                    <measurement group_id="B3" value="31" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="B4" value="31" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="B5" value="31" lower_limit="21" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Solicted Adverse Events</title>
        <description>The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant.</description>
        <time_frame>three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>30µg HA Vaccine</title>
            <description>30µg HA vaccine Intramuscularly administered Influenza vaccine: Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
          </group>
          <group group_id="O2">
            <title>1.5µg HA Adjuvanted</title>
            <description>1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
          </group>
          <group group_id="O3">
            <title>7.5µg HA Adjuvanted</title>
            <description>7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
          </group>
          <group group_id="O4">
            <title>30µg HA Adjuvanted</title>
            <description>30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
          </group>
        </group_list>
        <measure>
          <title>Solicted Adverse Events</title>
          <description>The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <time_frame>42 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.5µg HA Adjuvanted</title>
            <description>1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
          </group>
          <group group_id="O2">
            <title>30µg HA Vaccine</title>
            <description>30µg HA vaccine Intramuscularly administered</description>
          </group>
          <group group_id="O3">
            <title>7.5µg HA Adjuvanted</title>
            <description>7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
          </group>
          <group group_id="O4">
            <title>30µg HA Adjuvanted</title>
            <description>30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine</title>
        <description>Number of participants with haemagglutination inhibition tigers &gt;= 32 at the long term time point (1 year post vaccination).</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.5µg HA Adjuvanted</title>
            <description>1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
          </group>
          <group group_id="O2">
            <title>30µg HA Vaccine</title>
            <description>30µg HA vaccine Intramuscularly administered</description>
          </group>
          <group group_id="O3">
            <title>7.5µg HA Adjuvanted</title>
            <description>7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
          </group>
          <group group_id="O4">
            <title>30µg HA Adjuvanted</title>
            <description>30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine</title>
          <description>Number of participants with haemagglutination inhibition tigers &gt;= 32 at the long term time point (1 year post vaccination).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE were solicited for 42 days after vaccination</time_frame>
      <desc>Each participant received an AE form which was returned to the clinic 21 days after each vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>30µg HA Vaccine</title>
          <description>30µg HA vaccine Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="E2">
          <title>1.5µg HA Adjuvanted</title>
          <description>1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="E3">
          <title>7.5µg HA Adjuvanted</title>
          <description>7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
        <group group_id="E4">
          <title>30µg HA Adjuvanted</title>
          <description>30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>local or systemic reactions</sub_title>
                <description>Local: redness, local itching, oedema/local swelling, pain at the injection site, ecchymosis, hardness/induration; Systemic: fever, malaise, shivering/chills, fatigue, headache, sweating, myalgia, arthralgia, respiratory symptoms and diarrhoea.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Rebecca Jane Cox</name_or_title>
      <organization>University of Bergen</organization>
      <phone>+4755974668</phone>
      <email>rebecca.cox@uib.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

